# Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS

> **NCT05267821** · PHASE2,PHASE3 · RECRUITING · sponsor: **Nationwide Children's Hospital** · enrollment: 500 (estimated)

## Conditions studied

- Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)

## Interventions

- **DRUG:** Anakinra
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05267821
- **Lead sponsor:** Nationwide Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-14
- **Primary completion:** 2028-05-15
- **Final completion:** 2028-08-31
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05267821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05267821, "Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05267821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*